Brief: Camurus Says CAM2029 Well Tolerated With No New Safety Findings
18/06/2025 07:06
June 18 (Reuters) - Camurus AB CAMX.ST: CAM2029 WELL TOLERATED WITH NO NEW SAFETY FINDINGS CAM2029 GRANTED ORPHAN DRUG DESIGNATION FOR PLD IN US AND EU Source text: ID:nWkr57CkPk Further company coverage: CAMX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat